

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
29 June 2023 (29.06.2023)



(10) International Publication Number  
**WO 2023/122588 A3**

- (51) **International Patent Classification:**  
*C07D 257/02* (2006.01) *A61P 35/00* (2006.01)  
*A61K 51/10* (2006.01)
- (21) **International Application Number:**  
PCT/US2022/082021
- (22) **International Filing Date:**  
20 December 2022 (20.12.2022)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**  
63/291,910 20 December 2021 (20.12.2021) US
- (71) **Applicants:** **FUSION PHARMACEUTICALS INC.** [CA/CA]; 270 Longwood Road South, Hamilton, Ontario L8P 0A6 (CA). **ASTRAZENECA UK LIMITED** [GB/GB]; 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA (GB).
- (72) **Inventors:** **AGHEVLIAN, Sadaf**; 15 Legion Road, Etobicoke, Ontario M8V0A9 (CA). **GRINSHTEIN, Natalie**; 3630 212th Pl. SE, Bothell, Washington 98021 (US). **DUFFY, Ian, R.**; 268 Ellen Davidson Drive, Oakville, Ontario L6M 0V2 (CA). **KOSTELNIK, Thomas, I.**; 199 Catharine Street N, Hamilton, Ontario L8L 4S4 (CA). **BUCHANAN, Andrew, Grier**; Milstein Building, Granta Park, Cambridge CB21 6GH (GB). **MAZOR, Yariv**; One MedImmune Way, Gaithersburg, Maryland 20878 (US). **KASTURIRANGAN, Srinath**; One MedImmune Way, Gaithersburg, Maryland 20878 (US). **DU, Qun**; One MedImmune Way, Gaithersburg, Maryland 20878 (US). **YANG, Chunning**; One MedImmune Way, Gaithersburg,

Maryland 20878 (US). **COMER, Frank, Irvine**; One MedImmune Way, Gaithersburg, Maryland 20878 (US).

(74) **Agent:** **JACOBSTEIN, Jeffrey, M.** et al.; Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, 901 New York Avenue, NW, Washington, D.C. 20001-4413 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) **Title:** EGFR-CMET-TARGETED COMPOUNDS AND USES THEREOF

(57) **Abstract:** Compounds, e.g., radioimmunoconjugates, including a chelating moiety or a metal complex thereof, a linker, and an antibody or antigen-binding fragment thereof targeting both EGFR and cMET. Pharmaceutical compositions of such compounds and methods of treatment for conditions, e.g., cancer, using such compounds or pharmaceutical compositions.




FIG. 1A

WO 2023/122588 A3

[Continued on next page]

**Published:**

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

**(88) Date of publication of the international search report:**  
21 September 2023 (21.09.2023)